Real-World tracking begins for rare disease treatment
NCT ID NCT07109375
Summary
This study aims to collect long-term information on how well and how safely a medication called pegunigalsidase alfa works for adults with Fabry disease. It will follow about 75 patients who are already taking or planning to start this treatment in their normal healthcare settings. The main goal is to see how the treatment affects heart structure, heart function, and kidney health over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Federico II, Dipartimento di Nefrologia
Naples, Italy
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.